Literature DB >> 1357355

Cladribine (2-chlorodeoxyadenosine)

E Beutler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1357355     DOI： 10.1016/0140-6736(92)92826-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  71 in total

1.  Local application of antimycotics in mucormycosis cerebri: a case report.

Authors:  I Mohsenipour; M Schirmer; R Frank; F Geisen; E Semenitz; D zur Nedden; G Konwalinka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 2.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Immunosuppressive agents in multiple sclerosis.

Authors:  Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

4.  Phase II clinical study of cladribine in the treatment of hairy cell leukemia.

Authors:  Takashi Machii; Takaaki Chou; Muneou Suzuki; Yokiko Ohe; Shuichi Katagiri; E Kiyoshi Kitano; Kiyoshi Kitano; Yoshihide Fujiyama; Tooru Izumi; Chihiro Shimazaki; Koji Nanba; Yasuo Ohashi; Teruo Kitani
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

5.  Promising treatments of tomorrow for multiple sclerosis.

Authors:  Daniel M Harrison; Peter A Calabresi
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

6.  Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.

Authors:  Federico Carlini; Federico Ivaldi; Francesca Gualandi; Ursula Boschert; Diego Centonze; Giuseppe Matarese; Marco Salvetti; Nicole Kerlero de Rosbo; Antonio Uccelli
Journal:  J Neuroimmune Pharmacol       Date:  2021-04-14       Impact factor: 4.147

7.  My treatment approach to hairy cell leukemia.

Authors:  Rahul R Naik; Alan Saven
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

8.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

9.  Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato Masuda; Fumio Kawano; Masao Matsuoka; Hirokuni Taguchi; Torahiko Makino; Yoshinobu Asano; Kazuo Tamura; Yasuo Ohashi
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

10.  The treatment of chronic progressive multiple sclerosis with cladribine.

Authors:  E Beutler; J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.